How to Optimize CAR-T Transfection for Higher Gene Delivery and CAR Expression?

CAR-T cell therapy has transformed the way researchers approach cancer immunotherapy, but producing effective CAR-T cells still depends on a critical engineering challenge: delivering the CAR genetic material into T cells efficiently enough to generate strong and reproducible CAR expression without compromising cell health. This challenge becomes particularly important when working with primary human T cells. Unlike many established cell lines, primary T cells can be difficult to transfect and may respond strongly to changes in delivery conditions. A formulation that performs well in one donor may produce substantially different results in another. Increasing the amount of nucleic acid or extending the exposure time may improve delivery in some cases, but can also increase cellular stress and reduce recovery. For this reason, CAR-T transfection optimization should be viewed as a balance between delivery efficiency, CAR expression, cell viability, and process consistency. The delivery platform, transfection parameters, CAR construct, and RNA properties all contribute to the final outcome.

Why CAR-T Transfection Efficiency Is Only Part of the Story

A high transfection rate is an attractive result, but it does not necessarily indicate that the resulting CAR-T cells will perform better. For example, a delivery system may introduce genetic material into a large proportion of cells while causing considerable cellular stress. Another system may achieve a slightly lower delivery rate but preserve much better viability and recovery. If the ultimate objective is to generate a functional CAR-T cell population, the second condition may be more useful. CAR expression also needs to be considered beyond the percentage of CAR-positive cells. The amount of CAR present on the cell surface, the stability of expression, and the ability of engineered cells to survive and expand can all influence the quality of the final cell population. This is why CAR-T transfection optimization should evaluate gene delivery and cellular fitness together rather than treating transfection efficiency as the only performance indicator.

Selecting the Right CAR Gene Delivery Platform

The delivery technology establishes the foundation for CAR expression. Viral vectors, particularly lentiviral and retroviral vectors, remain among the most established approaches for stable CAR gene transfer. Their ability to efficiently introduce genetic material into T cells and support persistent expression has made them important tools for CAR-T development. However, viral-vector performance can vary with vector quality, production conditions, T-cell characteristics, and donor-to-donor variability. Viral-vector manufacturing itself can therefore become an important optimization target. Parameters such as the production cell line, culture medium, plasmid quantity, transfection reagent, reagent-to-DNA ratio, and harvesting conditions can influence vector yield. Improving vector production can subsequently improve downstream T-cell transduction without necessarily increasing the amount of vector used during T-cell engineering.

Nonviral technologies provide another route. Electroporation can introduce CAR mRNA efficiently into T cells and is particularly useful when transient CAR expression is preferred. Because mRNA does not need to integrate into the genome, this approach can provide rapid expression while avoiding the requirements associated with integrating viral vectors. Lipid-based delivery systems and newer nanoparticle technologies are also attracting attention for CAR-T engineering. These platforms may provide greater flexibility in cargo selection and formulation and can potentially be adapted to specific T-cell populations. The most appropriate platform therefore depends on whether the research objective requires stable or transient expression, the type of genetic cargo being delivered, the desired manufacturing workflow, and the acceptable balance between efficiency and cellular stress.

Optimizing the Transfection Process for Primary T Cells

Once a delivery platform has been selected, the next challenge is finding conditions that provide efficient intracellular delivery while maintaining T-cell fitness. Nucleic acid concentration is one of the most obvious parameters to investigate, but more is not always better. Increasing the amount of DNA or RNA can improve the probability of cellular uptake, but excessive cargo can also increase toxicity or place additional stress on the cells. For lipid-based systems, the relationship between nucleic acid and carrier concentration can be particularly important. Changes in the lipid-to-nucleic-acid ratio can alter particle formation, cellular uptake, endosomal processing, and ultimately cytoplasmic availability of the cargo. Incubation time can also influence the outcome. Longer exposure may increase cellular uptake, but extended contact with the delivery formulation can negatively affect cell viability. Similarly, cell density and the condition of the cells during exposure can alter the effective delivery environment. These parameters are best optimized experimentally rather than assumed to have a universally optimal value. Small-scale screening can help identify a useful operating range before a formulation is evaluated in larger experiments.

The Biological State of T Cells Matters

One of the most underestimated variables in CAR-T transfection is the state of the T cells themselves. Primary T cells are highly responsive to their environment. Activation status, culture conditions, T-cell subset, donor variability, and cellular metabolism can all influence how cells respond to genetic delivery. This explains why the same transfection formulation can behave differently across experiments. A condition optimized using one donor may not perform identically with another donor, even when the same protocol and reagents are used. The timing of genetic delivery relative to T-cell activation can therefore be an important development variable. Researchers should consider not only how efficiently the cells receive the cargo but also whether the delivery process disrupts subsequent recovery, proliferation, or phenotype. A robust CAR-T transfection workflow should ultimately be evaluated across representative T-cell preparations rather than optimized around a single biological sample.

Improving Viral Vector Production Before Transduction

For viral CAR gene delivery, downstream transduction efficiency can be strongly influenced by upstream vector production. The production system determines how much functional vector is available for T-cell engineering. Culture medium, production-cell condition, plasmid composition, DNA quantity, transfection reagent, and reagent-to-DNA ratio can all affect vector yield. Optimization studies have shown that seemingly routine production variables can substantially influence viral titers. This makes upstream process optimization an important part of improving CAR-T transduction rather than treating the viral vector as a fixed input. A consistent production process is particularly important when reproducibility matters. If vector quality varies between batches, it becomes difficult to determine whether changes in T-cell transduction originate from the cellular process or from the vector itself. Improving the consistency of vector production can therefore make downstream CAR expression easier to control and reduce unnecessary adjustments to the T-cell transduction process.

Designing the CAR Construct for Efficient Expression

Efficient delivery does not guarantee efficient CAR production. Once the genetic material enters the T cell, the sequence and architecture of the CAR construct become important determinants of expression. Codon optimization is commonly used to adapt the coding sequence to the translational preferences of human cells and can help improve protein production. Sequence composition also deserves attention during construct design. Repetitive regions, problematic secondary structures, unfavorable sequence motifs, and other unstable elements can complicate cloning, reduce transcript stability, or interfere with expression. The CAR architecture itself can influence surface expression. Differences in the antigen-binding domain, hinge, transmembrane region, and intracellular signaling domains may affect protein folding, trafficking, receptor stability, and cell-surface abundance. This distinction is useful when troubleshooting. If genetic delivery is efficient but surface CAR expression remains low, increasing the transfection reagent may not solve the underlying problem. The CAR sequence or protein architecture may instead require optimization.

Using Expression Tags for CAR Validation

Expression tags can provide an additional way to evaluate CAR production during research-stage development. Tags such as FLAG or Myc can facilitate detection of the engineered protein and help researchers distinguish between successful genetic delivery and actual protein expression. This can be particularly useful when comparing different CAR constructs or investigating why similar delivery conditions produce different levels of surface expression. However, tagged constructs should be evaluated carefully because the location of the tag and the specific CAR architecture can potentially influence protein behavior. When the goal is to characterize the final therapeutic construct, validation should ultimately focus on the unmodified or intended clinical-format CAR.

Improving CAR mRNA Performance

For transient CAR-T engineering, delivery is only one component of the problem. The properties of the mRNA can strongly influence how long and how efficiently the CAR is expressed. mRNA engineering can involve optimization of the coding sequence, untranslated regions, nucleotide composition, and other sequence features that affect stability and translation. Codon optimization can support efficient protein production while appropriate RNA engineering can help reduce undesirable innate immune responses. This becomes particularly important when transient expression is too short for the intended application. Simply increasing the amount of mRNA may not provide a proportional improvement if intracellular RNA stability or translation becomes the limiting factor. Emerging RNA formats such as circular RNA are being explored as another way to extend intracellular persistence and potentially maintain protein expression for longer periods. These approaches could expand the possibilities for nonintegrating CAR-T engineering. The key consideration is that initial CAR expression and expression duration are separate characteristics. A successful optimization strategy needs to define which of these properties is actually required for the intended application.

Exploring Lipid and Nanoparticle-Based Delivery

Lipid-based systems offer considerable flexibility for CAR-T genetic engineering because their composition can be modified to influence cellular uptake and intracellular cargo release. For primary T cells, this is especially important because conventional lipid formulations designed for easier-to-transfect cell types may not provide the same performance in T cells. Differences in membrane composition, endocytosis, intracellular trafficking, and innate immune responses can all affect delivery. Ionizable lipid systems are receiving increasing attention because their charge characteristics can be tuned according to the requirements of nucleic acid encapsulation and intracellular delivery. Computational and AI-assisted approaches are also beginning to influence lipid discovery. Instead of relying exclusively on conventional trial-and-error screening, researchers can use data-driven approaches to identify lipid structures and formulations with potentially improved delivery properties. These technologies may ultimately enable more selective delivery to T cells while reducing the need for highly aggressive transfection conditions.

Considering Repeated Delivery

Repeated administration of a nonviral delivery formulation is another strategy that can be explored when a single treatment does not provide sufficient cumulative gene delivery. For example, multiple exposures to a lipid-based system may increase the overall fraction of cells receiving the desired cargo. However, repeated treatment also increases the total exposure of the cells to the delivery system and may consequently affect viability or phenotype. The value of repeated delivery therefore depends on the specific formulation and biological system. Rather than assuming that more treatments will produce better CAR expression, researchers should determine whether additional delivery actually improves the number of viable CAR-expressing cells. This distinction is especially important for primary T cells, where cellular recovery can be as important as the initial delivery rate.

Moving Toward T-Cell-Specific Delivery

A major direction in CAR-T engineering is the development of delivery technologies designed specifically for T cells. Instead of treating T cells as generic target cells, newer platforms attempt to exploit their surface properties or cellular biology to improve cargo delivery. T-cell-specific fusion systems, engineered viral particles, and targeted nanoparticle technologies are examples of approaches being explored in this area. Some membrane-fusion-based systems have demonstrated efficient CAR mRNA delivery using relatively small amounts of cargo. Such technologies could potentially simplify CAR-T engineering by combining targeting and intracellular delivery in a single platform. This approach is conceptually different from simply increasing transfection strength. The goal is to make the delivery process more compatible with the biology of T cells.

Supporting T-Cell Expansion and Persistence

CAR expression is not necessarily the final endpoint of CAR-T development. The engineered cells also need to maintain appropriate viability, expansion capacity, and functional characteristics. For this reason, some development strategies investigate the co-delivery of supportive factors alongside the genetic material encoding the CAR. Cytokines such as IL-7 and IL-15 have been studied extensively in the context of T-cell maintenance and expansion. When incorporated into an engineering strategy, supportive signals may influence the survival and persistence of engineered cells. However, additional cargo also introduces additional formulation and manufacturing complexity. Co-delivery should therefore be driven by a specific biological requirement rather than used simply as a way to increase the number of components in the formulation.

Building a More Reproducible CAR-T Transfection Workflow

Optimization is not complete when the highest CAR expression observed in a single experiment has been identified. A useful CAR-T transfection process needs to tolerate biological and manufacturing variability. Donor differences, cell starting conditions, activation state, cargo quality, vector characteristics, and formulation variability can all affect the final result. For this reason, researchers should focus on identifying a robust operating range rather than a single ideal condition. A formulation that performs well across multiple experimental conditions is generally more valuable than one that delivers exceptional results only under a narrow set of circumstances. Small-scale optimization studies are particularly useful at this stage. They can help determine which parameters have the greatest influence on delivery and expression and can reduce unnecessary experimentation when the process moves toward larger-scale development.

How to Troubleshoot Poor CAR Expression

When CAR expression is lower than expected, the first step should be determining where the bottleneck occurs. If relatively few cells receive the genetic material, the delivery system or transfection conditions may need attention. If delivery appears efficient but CAR surface expression remains weak, the CAR construct, mRNA stability, translation efficiency, or intracellular trafficking may be limiting factors. If CAR expression is strong but cell recovery is poor, the delivery conditions may be too stressful. In this situation, increasing the amount of cargo may make the problem worse rather than better. Large differences between donors may indicate that the process is particularly sensitive to T-cell state. This is a strong reason to evaluate promising conditions using multiple T-cell preparations before considering them robust. This troubleshooting mindset can prevent a common mistake in CAR-T engineering: attempting to solve every problem by increasing the intensity of the transfection process.

The Future of CAR-T Transfection Optimization

CAR-T transfection is moving toward a more integrated approach in which the delivery platform, genetic cargo, cell state, and expression profile are optimized together. Viral vectors will continue to play an important role in stable CAR gene transfer, while mRNA delivery, lipid nanoparticles, engineered fusion particles, and other nonviral systems are expanding the possibilities for transient and potentially more controllable CAR expression. At the same time, advances in sequence engineering, RNA optimization, targeted delivery, and AI-assisted lipid discovery are creating opportunities to improve efficiency without relying solely on stronger transfection conditions. The most promising workflows will likely be those that treat CAR-T engineering as a complete biological system rather than optimizing a single parameter in isolation.

Conclusion

Higher CAR-T transfection efficiency does not necessarily come from using more genetic material or stronger delivery conditions. The quality of the final engineered cell population depends on how effectively the delivery platform, transfection process, CAR construct, and cellular environment work together. Viral-vector production can be optimized to improve consistency and transduction performance. Electroporation and lipid-based systems can be tuned for transient mRNA delivery. CAR sequence design can improve translation and surface expression, while RNA engineering can influence expression stability and duration. New targeted and AI-assisted delivery technologies may further improve the efficiency and selectivity of genetic engineering in primary T cells. Ultimately, the most useful CAR-T transfection strategy is not simply the one that produces the highest percentage of CAR-positive cells. It is the strategy that consistently generates a healthy, viable population of CAR-expressing T cells with the expression profile and functional characteristics required for the intended application.

Related Products